#USA #New York #Class Action #Gross Law Firm #ESSA Pharma

Alert for ESSA Pharma Shareholders

Investors holding shares in ESSA Pharma Inc. (NASDAQ: EPIX) should pay close attention to an important notice issued by The Gross Law Firm regarding potential class action litigation. Shareholders who acquired shares between December 12, 2023, and October 31, 2024, may be entitled to participate in a class action lawsuit. This follows allegations of misleading statements made by the company concerning the effectiveness of its drug treatment.

Background of the Case

The allegations focus on the drug masofaniten, which was said to be used in combination with enzalutamide. According to the complaint, ESSA Pharma misrepresented the efficacy of this combination, as it allegedly did not provide a significant benefit over enzalutamide alone. It is believed that misleading information about the drug's capabilities could have inflated the company's stock price, resulting in financial losses for its investors.

Details of the Class Action

Shareholders are encouraged to reach out to The Gross Law Firm to discuss their eligibility for participation in the class action. Although formal lead plaintiff appointment is not mandatory, it allows an individual to take a more active role in the litigation process. The firm assures that there will be no cost or obligation for those who register.

Important Deadlines

The deadline for shareholders to register for potential lead plaintiff status is March 25, 2025. This date marks a crucial turning point in the process, and timely action is advised for every affected shareholder.

What to Expect

Once registered, investors can keep track of the case's progress through a dedicated portfolio monitoring software provided by The Gross Law Firm. This will offer updates and important notifications about the case lifecycle.

Why Choose The Gross Law Firm?

The Gross Law Firm prides itself on its commitment to safeguarding investors’ rights in cases involving deceitful practices. As a nationally recognized firm specializing in class action lawsuits, it works diligently to challenge corporations that fail to uphold essential business ethics. Their ethos is firmly rooted in restoring losses sustained by investors due to false reports and misleading business practices.

How to Get Involved

Interested shareholders should not hesitate to register their information through the provided link for more details on participation and to help build a case against misleading practices by ESSA Pharma.

For further inquiries, The Gross Law Firm can be contacted directly:

• - Address: 15 West 38th Street, 12th Floor, New York, NY, 10018
• - Email: contact@grosslawfirm.com
• - Phone: (646) 453-8903

Remember, your involvement could possibly lead to the recovery of lost investments caused by misleading statements. Act now to ensure that your voice and financial interests are recognized.